Manher Joshi - 21 Jan 2026 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
23 Jan 2026, 18:04:03 UTC
Prior SEC filing
12 Nov 2025
Next SEC filing
18 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Anish Bhatnagar, Attorney-in-Fact

Key filing fact

Manher Joshi filed Form 4 for SOLENO THERAPEUTICS INC (SLNO) on 23 Jan 2026.

Key facts

  • This page summarizes Manher Joshi's Form 4 filing for SOLENO THERAPEUTICS INC (SLNO).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 23 Jan 2026, 18:04.

Change

  • Previous filing in this sequence was filed on 12 Nov 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001978048 Primary reporting owner

Joshi Manher

Relationship
Chief Development Officer
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Signature date
23 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLNO transaction

Common Stock

Award

Transaction value
$0
Shares
+4,100
Change %
+26%
Price
$0.000000
Shares after
20,171
Date
21 Jan 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLNO transaction Derivative

Employee stock option (right to buy)

Award

Transaction value
$0
Shares
+4,700
Change %
Price
$0.000000
Shares after
4,700
Date
21 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,700
Exercise price
$43.65
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

Footnote F2

These securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Footnote F3

1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .